Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Amado, RG" or (type exact bookEditor and editor="Amado, RG")

Add to list
Association of Progression-free Survival, Overall Survival, and Patient-reported Outcomes by Skin Toxicity and KRAS Status in Patients Receiving Panitumumab Monotherapy

Marc Peeters (UGent) , S Siena, E Van Cutsem, A Sobrero, A Hendlisz, S Cascinu, H Kalofonos, G Devercelli, M Wolf and RG Amado

(2009) CANCER. 115(7). p.1544-1554
Add to list
- Journal Article
- A1
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

RG AMADO, M WOLF, Marc Peeters (UGent) , E VAN CUTSEM, S SIENA, DJ FREEMAN, T JUAN, R SIKORSKI, S SUGGS, R RADINSKY, et al.

(2008) JOURNAL OF CLINICAL ONCOLOGY. 26(10). p.1626-1634
Add to list
- Journal Article
- A1
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy

E VAN CUTSEM, S SIENA, Y HUMBLET, JL CANON, J MAUREL, E BAJETTA, B NEYNS, D KOTASEK, A SANTORO, W SCHEITHAUER, et al.

(2008) ANNALS OF ONCOLOGY. 19(1). p.92-98
Add to list
- Journal Article
- A1
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

E VAN CUTSEM, Marc Peeters (UGent) , S SIENA, Y HUMBLET, A HENDLISZ, B NEYNS, JL CANON, JL VAN LAETHEM, J MAUREL, G RICHARDSON, et al.

(2007) JOURNAL OF CLINICAL ONCOLOGY. 25(13). p.1658-1664
Add to list
- Journal Article
- A1
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab

S SIENA, Marc Peeters (UGent) , E VAN CUTSEM, Y HUMBLET, P CONTE, E BAJETTA, D COMANDINI, G BODOKY, G VAN HAZEL, T SALEK, et al.

(2007) BRITISH JOURNAL OF CANCER. 97(11). p.1469-1474

Academic Bibliography

Association of Progression-free Survival, Overall Survival, and Patient-reported Outcomes by Skin Toxicity and KRAS Status in Patients Receiving Panitumumab Monotherapy

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab

Contents

Support

Contact